secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001299130-23-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio reports Q4 preliminary revenue $27.3M (-24% YoY); received orders for 76 Revio systems
--------------------------------------------------------------------------------

- Q4 2022 preliminary revenue $27.3M, down 24% from $36.0M in Q4 2021.
- Full-year 2022 preliminary revenue $128.2M, down 2% from 2021.
- Received orders for 76 Revio systems in Q4 2022, record product announcement.
- Cash, cash equivalents, and investments ~$772.3M as of Dec 31, 2022.
- Onso beta feedback positive; orders expected Q1 2023, shipments by end of Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913023000010/0001299130-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913023000010/pacb-20230109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001299130-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer